Vertex Pharmaceuticals, Inc’s filing revealed that its EVP, Chief Reg. & Quality Off. Tatsis Ourania unloaded Company’s shares for reported $2.14 million on Jan 07 ’26. In the deal valued at $474.99 per share,4,500 shares were sold. As a result of this transaction, Tatsis Ourania now holds 42,293 shares worth roughly $18.67 million.
Then, WAGNER CHARLES F JR sold 9,532 shares, generating $4,394,252 in total proceeds. Upon selling the shares at $461.00, the EVP, CO & FO now owns 37,725 shares.
Before that, Tatsis Ourania bought 4,500 shares. Vertex Pharmaceuticals, Inc shares valued at $2,137,455 were divested by the Officer at a price of $474.99 per share.
Bernstein upgraded its Vertex Pharmaceuticals, Inc [VRTX] rating to an Outperform from a a Mkt perform in a research note published recently. Wolfe Research also remained covering VRTX and has increased its forecast on January 06, 2026 with a “an Outperform” recommendation from previously “Peer perform” rating. Morgan Stanley revised its rating on December 03, 2025. It rated VRTX as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of VRTX
On Friday, Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] saw its stock jump 0.56% to $441.36. Over the last five days, the stock has lost -4.85%. Vertex Pharmaceuticals, Inc shares have risen nearly 4.03% since the year began. Nevertheless, the stocks have fallen -2.65% over the past one year.
How much short interest is there in Vertex Pharmaceuticals, Inc?
A steep rise in short interest was recorded in Vertex Pharmaceuticals, Inc stocks on 2025-12-31, growing by 0.57 million shares to a total of 5.02 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 4.46 million shares. There was a rise of 11.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 13, 2025 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating along with a $495 price target.
